Effect of mono or dual broncholdilator therapy on daily step count and six minutes walking distance in COPD patients.

Effect of mono or dual broncholdilator therapy on daily step count and six minutes walking distance in COPD patients. - Matsusaka Municipal Hospital COPD study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013616

Enrollment

Registered

2014-05-07

Start date

2014-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Single-arm trial(35 patients) Interventions will include 1)no-therapy for 3-to-4 weeks, 2)therapy with long-acting muscarinic antagonist alone for 3-to-4 weeks and 3)therapy with a combination of lon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients that fulfil the GOLD criteria and patients that agree to provide informed consent will be included.

Exclusion criteria

Exclusion criteria: 1.Patients with other serious clinical morbidities or complications will be excluded. 2.Patients with bronchial asthma 3.History of hypersensitivity to indacaterol and glycopyrronium 4.Patients during acute exacerabation 5.Patients who are judged improper to the test by an examination responsibility doctor's judgement

Design outcomes

Primary

Measure	Time frame
Average number of steps/day	—

Secondary

Measure	Time frame
Spirometry Quality of life 6-min walking distance test	—

Countries

Japan

Contacts

Public ContactOsamu Hataji

Matsusaka Municipal Hospital Respiratory center

mch1031@city-hosp.matsusaka.mie.jp0598-23-1515

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026